Adjuvant Alectinib Could Aid Disease-Free Survival in ALK-Positive NSCLC
A 76% lower risk was displayed with adjuvant alectinib compared to chemotherapy treatment for non–small cell lung cancer.
Source: pharmacytimes.com
Positive Lung News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Positive Lung. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Positive Lung Today - Breaking & Trending Today
HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated ...
— Oral presentation at the European Lung Cancer Congress 2024 of Phase IIIb data demonstrating median PFS of 13.7 months and median OS not reached in treatment-naïve patients —
Source: eagletribune.com
HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC
— Oral presentation at the European Lung Cancer Congress 2024 of Phase IIIb data demonstrating median PFS of 13.7 months and median OS not reached in treatment-naïve patients — — If...
Source: marketscreener.com
European Medicines Agency Validates Bristol Myers Squibb's Application for Repotrectinib for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer and NTRK-Positive Solid Tumors -January 02, 2024 at 07:00 am EST
Application based on data from the registrational TRIDENT-1 and CARE trials showing robust responses and durable activity in these patient populations If approved, repotrectinib will offer a...
Source: marketscreener.com
RETpositive and LUNGevity Foundation Partner on Innovative Lung Cancer Research Award
/PRNewswire/ -- Patient group RETpositive and LUNGevity Foundation today announced the 2022 recipients of the first RETpositive/LUNGevity Translational...
Source: prnewswire.com